Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier de Castro Carpeno

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|May 4, 2004
Do beta-tubulin pseudogenes really matter?Cristobal Belda-Iniesta, Rosario Perona, Javier de Castro Carpeno, et al.
Expert Review of Anticancer Therapy|September 25, 2014
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapyStefan Walzer, Christos Chouaid, Johanna Lister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Eicosapentaenoic acid as a targeted therapy for cancer cachexiaCristobal Belda-Iniesta, Javier de Castro Carpeno, Juan Angel Fresno Vara, et al.
JAMA Oncology|September 5, 2018
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical TrialCesare Gridelli, Javier de Castro Carpeno, Anne-Marie C Dingemans, et al.
Journal of Clinical Medicine|October 13, 2021
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-AnalysisMaría Rosario García Campelo, Edurne Arriola, Begoña Campos Balea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and BiomarkersSolange Peters, Rolf Stahel, Lukas Bubendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V Liu, Martin Reck, Aaron S Mansfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerHossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|May 4, 2004
Do beta-tubulin pseudogenes really matter?Cristobal Belda-Iniesta, Rosario Perona, Javier de Castro Carpeno, et al.
Expert Review of Anticancer Therapy|September 25, 2014
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapyStefan Walzer, Christos Chouaid, Johanna Lister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Eicosapentaenoic acid as a targeted therapy for cancer cachexiaCristobal Belda-Iniesta, Javier de Castro Carpeno, Juan Angel Fresno Vara, et al.
JAMA Oncology|September 5, 2018
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical TrialCesare Gridelli, Javier de Castro Carpeno, Anne-Marie C Dingemans, et al.
Journal of Clinical Medicine|October 13, 2021
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-AnalysisMaría Rosario García Campelo, Edurne Arriola, Begoña Campos Balea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and BiomarkersSolange Peters, Rolf Stahel, Lukas Bubendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V Liu, Martin Reck, Aaron S Mansfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerHossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
Pageof 1